Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Erlotinib, and Imatinib in Advanced Renal Cell Carcinoma
NCT00193258Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2004
- Primary completion
- Jan 2011
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of imatinib in clear cell renal cell carcinoma (ccRCC), sponsored by SCRI Development Innovations. Primary endpoints: Objective Response Rate at 18 months, Progression Free Survival at 18 months and 1 more. Started Jun 2004; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00193258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193258.